Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer - Full Text View

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

This study has been terminated.

Sponsored by:	Eli Lilly and Company
Information provided by:	Eli Lilly and Company
ClinicalTrials.gov Identifier:	NCT00055432

Purpose

This study hopes to evaluate whether the combination of Gemzar plus Alimta will have any beneficial effects for patients with recurrent platinum-sensitive or platinum-resistant ovarian or peritoneal cancer. Treatments are weekly for two weeks, with the 3rd week off and will be repeated every 21 days. Side effects and the overall safety of the treatment will also be monitored and evaluated. In addition, a Quality of Life questionnaire is part of this study to help measure patient perceived benefits or drawbacks to this treatment regimen.

Condition	Intervention	Phase
Ovarian Cancer Peritoneal Cancer	Drug: Gemzar and Alimta	Phase II

MedlinePlus related topics:

Cancer Ovarian Cancer

ChemIDplus related topics:

Gemcitabine hydrochloride Gemcitabine Pemetrexed disodium Pemetrexed Folic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must have disease that can be measured.
Patients must meet criteria for either platinum-resistant or platinum-sensitive ovarian or peritoneal cancer.
Patients may only have had one prior platinum-based chemotherapy regimen.
Patients must be willing and able to stop all aspirin and NSAID medications immediately before and for a time after each treatment cycle (approx. 5-8 days)
Patients must have normal kidney function.

Exclusion Criteria:

Patients may not have a Low Malignant Potential or Borderline Ovarian Tumor.
Patients may not have received pelvic or abdominal radiotherapy.
Patients must not have evidence of or received treatment for another cancer within the last 5 years.
Patients must not have been diagnosed with a heart attack in the last 6 months.
Patients who are unwilling or unable to take folic acid tablets, vitamin B12 injections or dexamethasone tablets.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00055432

Locations


United States, Georgia
	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
	Atlanta, Georgia, United States

Sponsors and Collaborators

Eli Lilly and Company

More Information

Study ID Numbers:	7127, H3E-US-JMFU
First Received:	March 3, 2003
Last Updated:	September 13, 2006
ClinicalTrials.gov Identifier:	NCT00055432
Health Authority:	United States: Food and Drug Administration

Keywords provided by Eli Lilly and Company:

recurrent ovarian cancer

platinum-resistant

platinum-sensitive

folate receptor antagonist

Study placed in the following topic categories:

Ovarian cancer

Ovarian Neoplasms

Gonadal Disorders

Genital Neoplasms, Female

Endocrine System Diseases

Urogenital Neoplasms

Ovarian Diseases

Recurrence

Pemetrexed

Genital Diseases, Female

Folic Acid

Endocrinopathy

Gemcitabine

Endocrine Gland Neoplasms

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

Adnexal Diseases

ClinicalTrials.gov processed this record on September 05, 2008